Acadia Pharmaceuticals Inc. (ACAD)
| Market Cap | 3.43B -4.7% |
| Revenue (ttm) | 1.14B +11.8% |
| Net Income | 380.48M +71.3% |
| EPS | 2.21 +66.4% |
| Shares Out | 172.31M |
| PE Ratio | 9.02 |
| Forward PE | 24.97 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,728,671 |
| Open | 19.95 |
| Previous Close | 20.15 |
| Day's Range | 19.59 - 20.19 |
| 52-Week Range | 19.60 - 30.96 |
| Beta | 0.86 |
| Analysts | Buy |
| Price Target | 32.16 (+61.69%) |
| Est. Earnings | Nov 4, 2026 |
About ACAD
Acadia Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting sy... [Read more]
Financial Performance
In 2025, Acadia Pharmaceuticals's revenue was $1.07 billion, an increase of 11.87% compared to the previous year's $957.80 million. Earnings were $391.00 million, an increase of 72.66%.
Financial StatementsAnalyst Summary
According to 20 analysts, the average rating for ACAD stock is "Buy." The 12-month stock price target is $32.16, which is an increase of 61.69% from the latest price.
News
Acadia Pharmaceuticals announces USPTO allowance of patent covering Trofinetide
Acadia Pharmaceuticals (ACAD) “announced that the United States Patent and Trademark Office – USPTO – has issued a Notice of Allowance for U.S. Patent Application No. 17/590,496, titled “Methods and…
Acadia Pharmaceuticals Announces Allowance of U.S. Patent Covering Weight-Banded Dosing of Trofinetide, extending U.S. patent protections to March 2041
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Appli...
Acadia price target lowered to $33 from $37 at H.C. Wainwright
H.C. Wainwright analyst Ananda Ghosh lowered the firm’s price target on Acadia Pharmaceuticals (ACAD) to $33 from $37 and keeps a Buy rating on the shares. The company’s Phase 2…
Acadia Pharmaceuticals price target lowered to $35 from $41 at Needham
Needham analyst Ami Fadia lowered the firm’s price target on Acadia Pharmaceuticals (ACAD) to $35 from $41 and keeps a Buy rating on the shares. The firm is updating its…
Acadia Pharmaceuticals price target lowered to $31 from $38 at Deutsche Bank
Deutsche Bank analyst David Hoang lowered the firm’s price target on Acadia Pharmaceuticals (ACAD) to $31 from $38 and keeps a Buy rating on the shares after topline data from…
Acadia Pharmaceuticals price target lowered to $34 from $36 at BMO Capital
BMO Capital lowered the firm’s price target on Acadia Pharmaceuticals (ACAD) to $34 from $36 and keeps an Outperform rating on the shares. The company’s RADIANT miss is a near-term…
Acadia Pharmaceuticals price target lowered to $33 from $36 at Citizens
Citizens lowered the firm’s price target on Acadia Pharmaceuticals (ACAD) to $33 from $36 and keeps an Outperform rating on the shares. Acadia’s RADIANT Phase 2 trial of remlifanserin narrowly…
Acadia Pharmaceuticals price target lowered to $33 from $40 at Citi
Citi analyst Yigal Nochomovitz lowered the firm’s price target on Acadia Pharmaceuticals (ACAD) to $33 from $40 and keeps a Buy rating on the shares after the company announced results…
Acadia Pharmaceuticals falls -10.2%
Acadia Pharmaceuticals (ACAD) is down -10.2%, or -$2.60 to $22.83.
Acadia Pharmaceuticals down 6% at $23.93 after update on Phase 2 RADIANT trial
08:00 EDT Acadia Pharmaceuticals (ACAD) down 6% at $23.93 after update on Phase 2 RADIANT trial
Acadia's Alzheimer's psychosis drug misses main goal of mid-stage study
Acadia Pharmaceuticals said on Thursday its experimental drug for psychosis associated with Alzheimer's missed the main goal of a mid-stage study testing whether it could reduce hallucinations and d...
Acadia Pharmaceuticals Transcript: Study result
Phase II results for remlifanserin in Alzheimer's psychosis showed the 60 mg dose narrowly missed significance on the primary endpoint but achieved nominal significance on a key secondary endpoint, with a favorable safety profile. The 60 mg dose will advance to phase III, with possible refinement of inclusion criteria to enhance efficacy.
Acadia Pharmaceuticals Press release: Study result
Acadia Pharmaceuticals issued a press release on September 24, 2026, disclosing material business information to investors.
Acadia Pharmaceuticals Slides: Study result
Acadia Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on September 24, 2026.
Acadia says Phase 2 portion of RADIANT trial ‘narrowly missed’ primary endpoint
Acadia Pharmaceuticals (ACAD) announced Phase 3 enabling topline results from the Phase 2 portion of the ongoing RADIANT clinical trial program evaluating remlifanserin for the treatment of hallucinat...
Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer's Disease Psychosis (ADP)
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced Phase 3 enabling topline results from the Phase 2 portion of the ongoing RADIANT clinical trial program evaluatin...
Acadia Pharmaceuticals price target raised to $38 from $37 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $38 from $37 and keeps a Buy rating on the shares.
Acadia Pharmaceuticals price target raised to $28 from $27 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $28 from $27 and keeps an Equal Weight rating on the shares after the European Commission has granted…
Acadia Pharmaceuticals price target raised to $40 from $39 at Citi
Citi raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $40 from $39 and keeps a Buy rating on the shares ahead of the Phase 2 Alzheimer’s disease psychosis…
Acadia Pharmaceuticals announces EC marketing authorization for Daybu
Acadia Pharmaceuticals (ACAD) announced that the European Commission, or EC, has granted marketing authorization for Daybu for the treatment of neurobehavioral symptoms of Rett syndrome in adults and ...
European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment o...
Acadia Pharmaceuticals price target raised to $49 from $45 at UBS
UBS raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $49 from $45 and keeps a Buy rating on the shares. Acadia is viewed favorably ahead of remlifanserin’s first…
Acadia Pharmaceuticals price target raised to $41 from $38 at Needham
Needham analyst Ami Fadia raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $41 from $38 and keeps a Buy rating on the shares. The firm is seeing an…
Acadia Pharmaceuticals Transcript: Canaccord Genuity's 46th Annual Growth Conference
NUPLAZID and DAYBUE continue to grow through education, expanded sales, and new formulations, with DAYBUE STIX rapidly gaining market share. European expansion is underway, and the pipeline, led by remlifanserin for Alzheimer's psychosis, targets large unmet needs.
Acadia Pharmaceuticals price target raised to $27 from $26 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $27 from $26 and keeps an Equal Weight rating on the shares.